{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T11:35:17Z","timestamp":1790508917741,"version":"4.1.0"},"reference-count":29,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2018,8,6]],"date-time":"2018-08-06T00:00:00Z","timestamp":1533513600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Patients with mantle cell lymphoma (<jats:styled-content style=\"fixed-case\">MCL<\/jats:styled-content>) generally have a dismal prognosis. Intensified induction treatment with rituximab and high dose cytarabine (R_HDAC), and consolidation with high\u2010dose therapy with autologous stem cell support has resulted in 10\u2010year overall survival (<jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content>) higher than 60%. However, the clinical course varies. Diagnostic tools capable of stratifying patients include the <jats:styled-content style=\"fixed-case\">MCL<\/jats:styled-content> International Prognostic Index (<jats:styled-content style=\"fixed-case\">MIPI<\/jats:styled-content>), gene expression\u2010based proliferation signature, Ki\u201067 proliferation index or tumour cell morphology. Here, we tested the performance of a newly developed Nanostring\u2010based <jats:styled-content style=\"fixed-case\">RNA<\/jats:styled-content> expression\u2010based proliferation assay (<jats:styled-content style=\"fixed-case\">MCL<\/jats:styled-content>35) on formalin\u2010fixed paraffin\u2010embedded tumour tissue from younger patients recruited in or treated according to Nordic <jats:styled-content style=\"fixed-case\">MCL<\/jats:styled-content> protocols compared to the prognosticators listed above. Seventy\u2010four patients were included and the assay performed well in all cases except four, which had inadequate <jats:styled-content style=\"fixed-case\">RNA<\/jats:styled-content> quality. The patients were evenly distributed in the <jats:styled-content style=\"fixed-case\">MCL<\/jats:styled-content>35 low\u2010, intermediate\u2010 and high\u2010risk categories. <jats:styled-content style=\"fixed-case\">MCL<\/jats:styled-content>35 low\u2010 and intermediate\u2010 risk groups had overlapping progression\u2010free survival (<jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content>), while patients in the high\u2010risk category had significantly inferior <jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content>. Combining <jats:styled-content style=\"fixed-case\">MCL<\/jats:styled-content>35 with <jats:styled-content style=\"fixed-case\">MIPI<\/jats:styled-content> or the <jats:styled-content style=\"fixed-case\">MIPI<\/jats:styled-content>\u2010C (<jats:styled-content style=\"fixed-case\">MIPI<\/jats:styled-content> with the addition of binary Ki67 score +\/\u221230%) showed a better discrimination than either assessment alone. In conclusion, the <jats:styled-content style=\"fixed-case\">MCL<\/jats:styled-content>35 assay alone or combined with <jats:styled-content style=\"fixed-case\">MIPI<\/jats:styled-content> or <jats:styled-content style=\"fixed-case\">MIPI<\/jats:styled-content>\u2010C scores can identify patients who still have a dismal outcome despite intensified treatment.<\/jats:p>","DOI":"10.1111\/bjh.15518","type":"journal-article","created":{"date-parts":[[2018,8,7]],"date-time":"2018-08-07T10:05:13Z","timestamp":1533636313000},"page":"225-234","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["The <scp>MCL<\/scp>35 gene expression proliferation assay predicts high\u2010risk <scp>MCL<\/scp> patients in a Norwegian cohort of younger patients given intensive first line therapy"],"prefix":"10.1111","volume":"183","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9799-9428","authenticated-orcid":false,"given":"Harald","family":"Holte","sequence":"first","affiliation":[{"name":"Department of Oncology Oslo University Hospital Oslo Norway"},{"name":"KG Jebsen Centre for B cell malignancies Institute for Clinical Medicine University of Oslo Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Beiske","sequence":"additional","affiliation":[{"name":"Department of Pathology Oslo University Hospital Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merrill","family":"Boyle","sequence":"additional","affiliation":[{"name":"Centre for Lymphoid Cancer British Columbia Cancer Agency Vancouver BC Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunhild","family":"Tr\u00f8en","sequence":"additional","affiliation":[{"name":"Department of Pathology Oslo University Hospital Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yngvild N.","family":"Blaker","sequence":"additional","affiliation":[{"name":"Department of Cancer Immunology Institute for Cancer Research Oslo University Hospital Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"June","family":"Myklebust","sequence":"additional","affiliation":[{"name":"KG Jebsen Centre for B cell malignancies Institute for Clinical Medicine University of Oslo Oslo Norway"},{"name":"Department of Cancer Immunology Institute for Cancer Research Oslo University Hospital Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunniva","family":"Kval\u00f8y","sequence":"additional","affiliation":[{"name":"Department of Surgery Vestfold Hospital Trust Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Rosenwald","sequence":"additional","affiliation":[{"name":"Institute of Pathology University of W\u00fcrzburg and Comprehensive Cancer Centre (CCC) Mainfranken W\u00fcrzburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole C.","family":"Lingj\u00e6rde","sequence":"additional","affiliation":[{"name":"Department of Informatics University of Oslo Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1268-2750","authenticated-orcid":false,"given":"Lisa M.","family":"Rimsza","sequence":"additional","affiliation":[{"name":"Laboratory Medicine and Pathology Mayo Clinic Scottsdale AZ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erlend B.","family":"Smeland","sequence":"additional","affiliation":[{"name":"KG Jebsen Centre for B cell malignancies Institute for Clinical Medicine University of Oslo Oslo Norway"},{"name":"Department of Cancer Immunology Institute for Cancer Research Oslo University Hospital Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Scott","sequence":"additional","affiliation":[{"name":"Centre for Lymphoid Cancer British Columbia Cancer Agency Vancouver BC Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Kolstad","sequence":"additional","affiliation":[{"name":"Department of Oncology Oslo University Hospital Oslo Norway"},{"name":"KG Jebsen Centre for Cancer Immunotherapy Institute for Clinical Medicine University of Oslo Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,8,6]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-559930"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-07-797019"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.4320"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.4490"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-117010"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds643"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu264"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00667-4"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-04-779736"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09174.x"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-095331"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.2466"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.8387"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-10-4079"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12308-009-0036-x"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200920"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-541953"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2002.01677.x"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.3700665"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(03)00028-X"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.095257"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-536433"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.7901"},{"key":"e_1_2_7_26_1","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. WHO Classification of Tumours","author":"Swerdlow S.H.","year":"2017"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05716.x"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00559-8"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306220"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00438-6"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.15518","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.15518","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T12:46:54Z","timestamp":1694868414000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.15518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,6]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["10.1111\/bjh.15518"],"URL":"https:\/\/doi.org\/10.1111\/bjh.15518","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,6]]},"assertion":[{"value":"2018-04-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-06-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-08-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}